BTIG lowered the firm’s price target on NeoGenomics (NEO) to $12 from $17 and keeps a Buy rating on the shares. The firm cites the company’s Q1 revenue miss and a lower revenue guide for its acquired Pathline business, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics: Hold Rating Amid Mixed Financial Performance and Market Conditions
- NeoGenomics Reports Strong Q1 2025 Performance
- NeoGenomics Reports Strong Q1 2025 Earnings Growth
- Optimistic Buy Rating for NeoGenomics Amid CEO Transition and Growth Potential
- Challenging Growth Outlook and Competitive Pressures Lead to Hold Rating for NeoGenomics